Publications

Detailed Information

Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies

Cited 49 time in Web of Science Cited 64 time in Scopus
Authors

Rugo, Hope S.; Turner, Nicholas C.; Finn, Richard S.; Joy, Anil A.; Verma, Sunil; Harbeck, Nadia; Masuda, Norikazu; Im, Seock-Ah; Huang, Xin; Kim, Sindy; Sun, Wan; Iyer, Shrividya; Schnell, Patrick; Bartlett, Cynthia Huang; Johnston, Stephen

Issue Date
2018-09
Publisher
Pergamon Press Ltd.
Citation
European Journal of Cancer, Vol.101, pp.123-133
Abstract
Aim: Because incidence of breast cancer and comorbidities increase with age, it is important to determine treatment benefit in elderly patients. We evaluated outcomes with palbociclib plus endocrine therapy in patients aged >= 65 years. Methods: Data were pooled from three randomised studies (NCT00721409, NCT01740427 and NCT01942135) of women with HR+/HER2- advanced breast cancer (ABC). In PALOMA-1 (open-label) and PALOMA-2 (double-blind, placebo-controlled), treatment-naive patients received palbociclib plus letrozole or letrozole alone. In PALOMA-3 (double-blind, placebo-controlled), patients with endocrine-resistant disease received palbociclib plus fulvestrant or fulvestrant alone. Results: Among 528 patients treated with palbociclib plus letrozole and 347 treated with palbociclib plus fulvestrant, 218 (41.3%) and 86 (24.8%), respectively, were aged >= 65 years. Versus endocrine therapy alone, median progression-free survival was significantly improved in patients aged 65-74 years (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.45-0.97; P = 0.016) and >= 75 years (HR, 0.31; 95% CI, 0.16-0.61; P<0.001) receiving palbociclib plus letrozole and in patients aged 65-74 years (HR, 0.27; 95% CI, 0.16-0.48; P<0.001) receiving palbociclib plus fulvestrant; few patients aged >= 75 years received palbociclib plus fulvestrant (HR, 0.59; 95% CI, 0.19-1.8; P = 0.18). Patient-reported functioning and quality of life was maintained. No clinically relevant differences in palbociclib exposure were observed between age groups. Although myelosuppression was more common among patients aged >= 75 years, incidence of grade >= III myelosuppression was similar across age groups, and febrile neutropenia was uncommon (<= 2.4%); no new safety concerns were identified in older patients. Conclusions: Palbociclib plus endocrine therapy is an effective, well-tolerated treatment for older patients with ABC. (C) 2018 Published by Elsevier Ltd.
ISSN
0959-8049
URI
https://hdl.handle.net/10371/177318
DOI
https://doi.org/10.1016/j.ejca.2018.05.017
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share